Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Change in Accured Expenses (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Change in Accured Expenses for 16 consecutive years, with -$68702.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Accured Expenses fell 21.64% year-over-year to -$68702.0, compared with a TTM value of $762943.0 through Sep 2025, up 520.43%, and an annual FY2024 reading of $432051.0, up 67.61% over the prior year.
  • Change in Accured Expenses was -$68702.0 for Q3 2025 at China Pharma Holdings, down from $187274.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $804339.0 in Q4 2022 and bottomed at -$450887.0 in Q1 2023.
  • Average Change in Accured Expenses over 5 years is $96331.8, with a median of $60704.0 recorded in 2021.
  • The sharpest move saw Change in Accured Expenses soared 1563.75% in 2021, then crashed 579.2% in 2022.
  • Year by year, Change in Accured Expenses stood at $207099.0 in 2021, then surged by 288.38% to $804339.0 in 2022, then crashed by 47.67% to $420886.0 in 2023, then surged by 73.44% to $729967.0 in 2024, then plummeted by 109.41% to -$68702.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for CPHI at -$68702.0 in Q3 2025, $187274.0 in Q2 2025, and -$85596.0 in Q1 2025.